On 28 September 2026, INNOVENT BIO (01801.HK) said Jaypirca won China's NMPA approval as a monotherapy for adult CLL/SLL patients across all lines of therapy.
On September 28, 2026, RoboSense (02498.HK) strengthened in afternoon trading. As of 14:05, it was quoted at HK$16.67, up 4.12%.
Hansoh (03692.HK) said the EU revoked the marketing authorisation for Aumolertinib (Aumseqa®) on 25 September over a procedural issue; a resubmission is planned.
On 24 Sept 2026, CSPC PHARMA (01093.HK) said its Phase III trial of Becotatug (JMT101) plus osimertinib in EGFR ex20ins NSCLC met the primary endpoint.
On 24 Sept 2026, LIFETECH SCI (01302.HK) said its SureCham aortic arch single-branched stent graft system entered the NMPA innovative device special review.
On 24 Sep 2026, UNITED LAB (03933.HK) said NMPA accepted the filing for its IDegLira once-daily diabetes shot, the first such biosimilar application in China.
On 24 Sep 2026, HANSOH PHARMA (03692.HK) said NMPA accepted the NDA for HS-20093, its B7-H3-targeting ADC, to treat osteosarcoma patients after 2+ prior lines.
On September 24, 2026, Hong Kong stocks closed slightly lower, with the HSI down 0.29%. HORIZONROBOT-W rose 2.22% while GIGADEVICE fell 5.12% on the day.
On 24 September 2026, CSPC PHARMA (01093.HK) said the Phase III trial of its albumin-bound docetaxel HB1801 for advanced breast cancer has started in China.
On September 24, 2026, XPENG-W (09868.HK) traded weaker. As of 15:46, it was quoted at HK$40.32, down 0.20%.
SMIC (00981.HK) fell 1.41% to HKD 62.900. TSMC will raise wafer out prices by 3%-6% from January 2027; CANYON SEMICONDUCTOR opened its ChiNext subscription.
UBTECH ROBOTICS (09880.HK) fell 1.26% to HKD 78.050. The 5th Global Digital Trade Expo opened in Hangzhou; Tesla's CEO forecast 100 billion humanoid robots.
On 24 September 2026, INNOCARE (09969.HK) inked a licensing deal with Eli Lilly on up to five targets, worth up to US$100M upfront and US$3.25B in milestones.
On 24 September 2026, MICROPORT NEURO (02172.HK) said its NuWismen® Liquid Embolic Agent entered the NMPA's Green Path, its eighth such product.
On 24 September 2026, HUTCHMED (00013.HK) said two Phase III studies of savolitinib plus osimertinib will be presented as ESMO 2026 orals.
On 23 Sep 2026, TIAN TU CAPITAL (01973.HK) agreed to invest US$25m in Topos AI Infra: ~16.7% of Holdings (US$5m) and ~40% of Investments (US$20m).
